Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arthrocare v. Smith & Nephew

This article was originally published in The Gray Sheet

Executive Summary

Patent infringement suit filed July 25 in Delaware state court alleges S&N's Dyonics Control RF bipolar arthroscopic radiofrequency surgical system infringes at least four Arthrocare patents related to the firm's Coblation surgical arthroscopy technology. The suit seeks an injunction against sales as well as treble damages. The Dyonics device was launched July 16

You may also be interested in...



Arthroscopy patent suit

Smith & Nephew will "vigorously pursue" an appeal of a May 12 jury decision in Wilmington, Del. district court declaring infringement of three ArthroCare Coblation patents. Faced with market removal or licensure of its Dyonics Control RF, Saphyre and ElectroBlade arthroscopy devices, S&N contends it has "strong grounds" for appeal. ArthroCare forecasts a damages trial will be held within the next three months. Filed in July 2001, the suit asserted 16 infringement claims within the ArthroCare patents (1"The Gray Sheet" July 30, 2001, In Brief). The Delaware jury found S&N directly infringed, induced and contributed to infringement on all 16 claims. Barring settlement, ArthroCare says it will request an injunction against the S&N products...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel